Arabinopyranosyl-N-methyl-N-nitrosourea

Lore & Background

Arabinopyranosyl-N-methyl-N-nitrosourea was first synthesized in the late 1970s in the Laboratory of Organic Synthesis of the Soviet Cancer Research Institute, which belonged to the Academy of Medical Sciences of the USSR. Its first clinical trials in the USSR were conducted in the late 1980s, confirming potential clinical efficacy in melanoma and better relative safety and improved tolerability over other nitrosourea antineoplastic compounds available at that time. In 1996, the compound obtained regulatory approval from the Russian Pharmacologic Committee for use in melanoma under the trade name Aranoza.

Reader's Guide

The significance of Arabinopyranosyl-N-methyl-N-nitrosourea lies in its development as a Soviet-era chemotherapeutic agent designed to improve upon existing nitrosoureas. Its chemical structure conjugates the cytotoxic N-nitroso-N-methylurea residue with L-arabinose, a sugar component of other anticancer drugs like cytarabine and fludarabine. This L-arabinoside residue was claimed to improve penetration into malignant cells and across the blood–brain barrier while reducing toxicity to normally fast-dividing cells, such as bone marrow and gastrointestinal mucosa. The drug acts by alkylating DNA, causing intra-strand adducts and cross-linking, which inhibits mitosis and promotes apoptosis. It is indicated for melanoma of the skin and eye, used in combination with dacarbazine and interferon-alpha. Preclinical trials also showed potential promise for experimental non-squamous cell lung cancer in combination with cisplatin and gemcitabine or with cisplatin and irinotecan. Its legacy includes being a Russian-approved alternative to other nitrosoureas, with claims of milder side effects at therapeutic doses compared to carmustine and lomustine.

Did You Know?

• It was developed in the Soviet Union in the 1970s.
• Its first clinical trials in the USSR were conducted in the late 1980s.
• It obtained Russian regulatory approval in 1996 for use in melanoma.
• The L-arabinose residue in its structure is also found in cytarabine and fludarabine.